Somatostatin receptors (SST), especially SST2A, are well known for their overexpression in well-differentiated gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN), where they serve as the molecular basis for SST-based diagnostics and treatment modalities. The gene discussed is SST; the disease is digestive system neuroendocrine neoplasm.